Baxter Q3 2023 adjusted EPS $0.68 from continuing ops beats guidance; completes $4.25B BPS divestiture

BAXTER INTERNATIONAL INC

2023-Q3 EPS reported $4.76 revenue$10,928,000,000

Q3 revenue from continuing ops $3.71B (+3% reported, +2% CC), ahead of company guidance.
GAAP EPS from continuing ops $0.09; adjusted EPS $0.68, exceeded prior guidance.
Completed BioPharma Solutions divestiture for $4.25B; cash proceeds $3.96B; gain $2.89B; debt repayment use.
Kidney Care spinoff on track to close by July 2024.
FY 2023 adjusted EPS guidance $2.57-$2.60; Q4 2023 adjusted EPS guidance $0.85-$0.88.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BAXTER INTERNATIONAL INC reported third quarter 2023 results: revenue $3.71 billion, net income $2.51 billion, EPS $4.93 per diluted share.

Period: third quarter 2023
Revenue: $3.71 billion
Net income: $2.51 billion
EPS: $4.93 per diluted share
Result: reported results

Exact text from the filing

BAXTER REPORTS THIRD-QUARTER 2023 RESULTS • Third-quarter revenue from continuing operations of $3.71 billion increased 3% on a reported basis and 2% on a constant currency basis, ahead of the company’s previously issued guidance 1 • Third-quarter U.S. GAAP earnings per share (EPS) from continuing operations of $0.09; adjusted EPS from continuing operations of $0.68 exceeded guidance • Third-quarter U.S. GAAP EPS in the aggregate (including discontinued operations) totaled $4.93; adjusted EPS in the aggregate (including discontinued operations) of $0.82 exceeded guidance

View on SEC.gov

Browse all earnings releases →

BAXTER INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0001628280-23-036194

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.